Neurological disorders affect hundreds of millions of people worldwide, and for many patients, existing treatments fall short. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is working to change that with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis (MS) and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS worldwide, about one million of those in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to MS, the company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This two-pronged approach addresses both chronic and acute neurological conditions, potentially impacting millions of patients who lack effective options.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
